C
C4 Therapeutics, Inc. (CCCC)
NMS – Real Time Price. Currency in USD
3.17
0.00 (0.00%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
3.17
0.00 (0.00%)
At close: May 12, 2026, 4:00 PM EDT
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Name | Position |
|---|---|
| Dr. Isabel Chiu Ph.D. | Senior Vice President of Strategic Alliances & Business Development |
| Dr. Kenneth C. Anderson M.D., Ph.D. | Co-Founder, Independent Director & Member of Scientific Advisory Board |
| Dr. Leonard M. J. Reyno M.D. | Chief Medical Officer |
| Dr. Nathanael S. Gray Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Mr. Andrew J. Hirsch M.B.A. | CEO, President & Director |
| Mr. Mark Mossler | Chief Accounting Officer |
| Ms. Courtney Solberg | Senior Manager of Investor Relations |
| Ms. Kelly A. Schick | Chief People Officer |
| Ms. Kendra R. Adams | Chief Financial Officer and Head of Corporate Affairs & Treasurer |
| Ms. Paige Mahaney Ph.D. | Chief Scientific Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-12 | 10-Q | cccc-20260331.htm |
| 2026-04-29 | DEFA14A | c4therapeuticsinc-proxydef.htm |
| 2026-04-29 | DEF 14A | cccc-20260429.htm |
| 2026-04-29 | ARS | cccc-20251231x10kars2026.htm |
| 2026-04-10 | 8-K | cccc-20260410.htm |
| 2026-04-09 | 8-K | cccc-20260409.htm |
| 2026-02-26 | S-8 | a2026s-8.htm |
| 2026-02-26 | 8-K | cccc-20260226.htm |
| 2026-01-14 | 8-K | cccc-20260114.htm |
| 2025-12-08 | CORRESP | filename1.htm |